THE FASTEST PATH TO THE CLINIC
For decades, the biotechnology industry has struggled to align complex functions towards a singular goal of getting to the clinic. The process is long, expensive, resource straining, and bursting with risk.
We believe the road to the clinic is difficult enough without the inefficiencies of traditional drug development, so we are offering a better solution. With our acquisition of Aptuit in 2017, Evotec is now the only organisation with the capability to successfully deliver fully-integrated drug discovery and development programmes.
We offer a two-tiered approach to the clinic
For a single or short list of candidates, this integrated package will fully de-risk your molecule before investing millions and months in clinical-enabling studies. In addition, this package will enhance the quality, speed of delivery, and probability of success for your clinical candidate.
Once your clinical candidate is selected, this fully-integrated clinical-enabling package focuses intensely on interdisciplinary coordination of all aspects of drug development, conducted and managed by a single Evotec team, and at a single Evotec site.
In bringing your candidate through IND filing “under one roof“, we will eliminate the inherent inefficiency of the traditional multiple-vendor approach by consolidating development to a single, cross-functional team with decades of drug development experience. All while increasing the probability and speed of success of your programme.
INDiGO key features
- Accelerated drug development through interdisciplinary integration and expert coordination of all drug development activities “under one roof”
- Industry-leading timelines from candidate nomination to regulatory submission